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Abstract
Background: The cellular prion protein (PrPc) is a host-encoded glycoprotein whose transconformation into PrP
scrapie (PrPSc) initiates prion diseases. The role of PrPc in health is still obscure, but many candidate functions have
been attributed to the protein, both in the immune and the nervous systems. Recent data show that experimental
autoimmune encephalomyelitis (EAE) is worsened in mice lacking PrPc. Disease exacerbation has been attributed
to T cells that would differentiate into more aggressive effectors when deprived of PrPc. However, alternative
interpretations such as reduced resistance of neurons to autoimmune insult and exacerbated gliosis leading to
neuronal deficits were not considered.
Method: To better discriminate the contribution of immune cells versus neural cells, reciprocal bone marrow
chimeras with differential expression of PrPc in the lymphoid or in the central nervous system (CNS) were
generated. Mice were subsequently challenged with MOG35-55 peptide and clinical disease as well as
histopathology were compared in both groups. Furthermore, to test directly the T cell hypothesis, we compared
the encephalitogenicity of adoptively transferred PrPc-deficient versus PrPc-sufficient, anti-MOG T cells.
Results: First, EAE exacerbation in PrPc-deficient mice was confirmed. Irradiation exacerbated EAE in all the
chimeras and controls, but disease was more severe in mice with a PrPc-deleted CNS and a normal immune
system than in the reciprocal construction. Moreover, there was no indication that anti-MOG responses were
different in PrPc-sufficient and PrPc-deficient mice. Paradoxically, PrPc-deficient anti-MOG 2D2 T cells were less
pathogenic than PrPc-expressing 2D2 T cells.
Conclusions: In view of the present data, it can be concluded that the origin of EAE exacerbation in PrPc-ablated
mice resides in the absence of the prion protein in the CNS. Furthermore, the absence of PrPc on both neural and
immune cells does not synergize for disease worsening. These conclusions highlight the critical role of PrPc in
maintaining the integrity of the CNS in situations of stress, especially during a neuroinflammatory insult.
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The prion protein (PrP) is a host-encoded glycoprotein
of 30-35 kD molecular weight which presents intri-
guing physicochemical and biological properties [1].
PrP can adopt at least two conformations: a “cellular”
isoform (PrPc) anchored at the membrane by a glyco-
sylphosphatidylinositol (GPI) residue and constitutively
expressed on many tissues, and a “scrapie” isoform
(PrPSc) rich in beta-pleated sheets, resistant to mana-
ged protease treatments and viewed as the propagating
agent of human and animal transmissible spongiform
encephalopathies (TSE) or prion diseases [2]. Another
important feature of PrP is its almost universal expres-
sion in vertebrate species including mammalians, birds,
amphibians and fish. The molecular structure of PrPc
is remarkably conserved in all these species with 2 dis-
tinct domains, a random coil flexible one characterized
by a series of octarepeats and a globular one contain-
ing 3 strictly oriented a-helices [3]. Such evolutionary
conservation suggests that the prion protein fulfills
ancient and still essential biological functions [4]. Para-
doxically, genetically-ablated mice display no major
alterations of reproductive, developmental, behavioral,
and immunological functions [5,6]. The fundamental
role in health of PrPc that justifies its evolutionary
conservation is still not elucidated and remains an
object of debate [7].
PrPc is most abundantly expressed on neural cells
including neurons and glia [8,9], as well as in subsets
of cells of hematopoietic origin [10,11]. Therefore, can-
didate functions have been essentially sought in the
immune and central nervous system (CNS). Compari-
son of PrPc-deficient with PrPc-sufficient mice, or
derived cell lines, has provided an extensive, some-
times contradictory and questionable list of candidate
functions in relation with cell adhesion, enzymatic
activity, signal transduction, copper metabolism, and
programmed cell death. In the nervous system, PrPc is
candidate for a wide range of functions relevant to
protection against ischemic trauma, apoptotic agents
and reactive oxygen species [12,13]. PrPc has been also
implicated in the preservation of neuronal transmission
[14], neurite outgrowth [15], synaptic plasticity [16],
circadian rhythm [17] and during aging, maintenance
of peripheral myelin [18] as well as motor behavior
and memory [19,20].
PrPc fulfills also important functions outside the CNS,
in particular in the immune system [21]. The prion pro-
tein is promptly upregulated in activated T lymphocytes
and is redistributed in lipid rafts, together with signaling
molecules [22,23]. The ablation or the masking of PrPc
with antibodies reduces T cell proliferation [24,25].
Upon MHC/peptide-driven interactions between T cells
and dendritic cells (DC), PrPc migrates at the immuno-
logical synapse and exerts differential effects on T cell
proliferation and cytokine production, revealed by abla-
tion or antibody masking on the DC or on the lympho-
cyte side of the synapse [22]. Beside its involvement in
adaptive immune responses, PrPc controls various
aspects of hematopoietic cell differentiation and function
including the self-renewal of bone marrow (BM) pro-
genitors [26], thymic differentiation [27], and the repres-
sion of phagocytic activity in macrophages [28]. Beside a
direct implication in TSE pathogenesis, as a substrate of
transconformation, PrPc has been involved in chronic
and acute neurodegenerative conditions including Alz-
heimer’s disease [29] and experimental autoimmune
encephalomyelitis (EAE). Three recent and independent
studies have reported that clinical and histological mani-
festations of EAE were worsened in mice which lacked
[30,31] or under-expressed PrPc [32]. The authors pro-
posed that PrPc acts as a regulatory molecule and that
T lymphocytes that lacked PrPc behaved more aggres-
sively against the CNS than wild type T cells. Alterna-
tive explanations such as reduced resistance of neurons
to autoimmune insults, or exacerbated aggressiveness of
glial cells [33] were either not considered [30,31], or
only partially explored [32]. In view of the ongoing
debate regarding the biological functions of PrPc, the
issue warranted further investigations. To this end, we
have engineered reciprocal BM chimeras differentially
expressing PrPc in the CNS or in the lymphoid com-
partment. Our results confirm that EAE is exacerbated
in PrPc-deficient mice, but in contrast to the previous
studies, they support the conclusion that the origin of
disease worsening lies in the absence of PrPc in neural
cells and not in lymphoid cells.
Methods
Mice
PrPc-ablated (Prnp
-/-) mice were derived from the Zur-
ich I strain [5]. The disrupted gene was backcrossed
onto C57BL/6 (B6) mice for more than 12 generations
[34]. PrPc-sufficient and PrPc-deficient mice were fully
compatible by reciprocal skin grafting (data not shown).
They were both kept on CD45.1 and CD45.2 back-
grounds. The 2D2 transgene encoding for an a/b Tc e l l
receptor (TCR) specific for myelin oligodendrocyte gly-
coprotein (MOG35-55) peptide [35] was backcrossed
onto Prnp
-/- mice for 7 generations. All the mice includ-
ing CD3ε knock-outs [36] were on a B6 background.
Animals were maintained under pathogen-free condi-
tions. All procedures were carried out in strict accor-
dance with the French legislation and European Treaty
ETS 123, and were approved by the Ethic Committee of
UPMC Univ Paris 6.
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Adult female mice (8-10 weeks old) were immunized at
the base of the tail with 200 μgo fM O G 35-55 peptide
(MEVGWYRSPFSRVVHLYRNGK, purity > 85%,
NeoMPS, Strasbourg, France) in phosphate buffer saline
(PBS) emulsified with an equal part of complete
Freund’s adjuvant (CFA) supplemented with Mycobac-
terium tuberculosis H37Ra at 6 mg/ml (Difco Labora-
tories, Detroit, MI). Mice received in addition 300 ng of
pertussis toxin injected intraperitoneally (i.p.) on days 0
and 2 (Calbiochem, Darmstadt, Germany). EAE was also
induced in CD3ε knock-out mice adoptively transferred
with 3 × 10
6 TCR-transgenic CD4+ 2D2 T cells expres-
sing or not PrPc.
EAE-induced mice were scored daily for clinical signs
of disease. Scoring was as follows: 0, no detectable signs;
0.5 partial limp tail; 1, complete limp tail; 1.5, limp tail
with hindlimb weakness or gait abnormality; 2, limp tail
with unilateral hindlimb paralysis; 3, bilateral hindlimb
paralysis; 4, bilateral hindlimb paralysis and forelimb
weakness; 5, bilateral forelimbs an hindlimbs paralysis
(endpoint). Ataxia (disruption of gait and of motor con-
trol) was evaluated independently as an index of cerebel-
lar dysfunction. Wild type and Prnp
-/- controls injected
with CFA/PBS plus pertussis toxin remained free of
neurological signs.
Mouse radiation chimeras
Four week-old Prnp
+/+ and Prnp
-/- female mice on a
CD45.1 background were subjected to 11 Gy total body
irradiation, and were intravenously reconstituted 16
hours later with BM cells (20 × 10
6) prepared from
femurs and tibias of CD45.2 gender-matched Prnp
+/+
and Prnp
-/- mice. Bactrim (sulfamethoxazole 0.2 mg/mL,
trimethoprim 0.04 mg/mL) was added to drinking water
for the 15 following days. Ten weeks after reconstitu-
tion, mice were immunized with MOG35-55 or PBS as
described above.
Flow cytometry analyses
Regulatory T cells were labeled with anti-CD4, anti-
CD25, and FoxP3 antibodies as previously described
[37]. Lymphoid compartments in reconstituted chimeras
were phenotyped with anti-CD4, anti-CD8, anti-CD19
and CD45.1 and CD45.2 antibodies. All antibodies were
from BD Bioscience (Le pont de Claix, France). Samples
were acquired on a two-laser Becton-Dickinson FACS-
can and analyzed with BD CellQuest and FlowJo soft-
ware (TreeStar, Ashland, Oregon, USA).
Cell-mediated and humoral responses against MOG
Spleen cells from Prnp
+/+ and Prnp
-/- mice were col-
lected at 22 days post-immunization (dpi). CD4+ T cells
enriched by negative magnetic selection (Dynabeads,
Invitrogen, France) were assayed for antigen-specific
proliferation and lymphokine release. Spleen DC serving
as a source of antigen-presenting cells (APC) were iso-
lated from non-immunized wild type mice by positive
selection on a CD11c magnetic kit (Miltenyi Biotec,
Paris, France). CD4+ T cells (2 × 10
5)w e r ep l a t e d
together with 3 × 10
4 DC per well. MOG peptide was
added at 100, 10, 1 and 0 μg/ml. Proliferation was mea-
sured by thymidine incorporation after 4-day culture, as
previously described [34]. Lymphokine release was
assessed in supernatants from replicate cultures col-
lected after 48 h. Concentrations of IFN-g and IL-17 in
c u l t u r es u p e r n a t a n t sw e r em e a s u r e db ys o l i dp h a s e
ELISA kit according to the manufacturer recommenda-
tions (PeproTech, Neuilly, France).
Anti-MOG antibodies were titrated by ELISA in sera
from MOG-induced mice at 22 dpi according to stan-
dard procedures [34]. Serum dilutions ranging from 1:50
to 1:2500 were distributed into polystyrene 96 well
ELISA plates (Maxisorp, Nunc, Denmark) pre-coated
with MOG35-55 peptide. Bound antibody was revealed
with goat anti-mouse IgM + IgG + IgA (H + L) immu-
noglobulin conjugated to alkaline phosphatase (Southern
Biotech, USA) and p-nitrophenyl phosphate as substrate.
Absorbance was measured at 405 nm. Results are
reported as optical density (OD).
Histology
A series of 6-8 five micrometer thick coronal sections of
paraffin embedded spinal cord (lumbar region) or cere-
bellum samples were stained with hematoxylin and
Bielschowsky silver impregnation to evaluate inflamma-
tory infiltrates and axonal loss respectively [38]. The
number of perivascular inflammatory foci per section
was first scored on spinal cords from Prnp
+/+ and
Prnp
-/- mice by two researchers blinded to the genotype.
Because differences in this inflammatory score were not
evidenced, the total number of white matter nuclei/
spinal cord section was also evaluated to assess the
extent of white matter immune cell infiltration. Histolo-
gical scores of axonal loss for individual animals were
evaluated blindly using a semi-quantitative grid where 0
is no disease and ascending numerical score indicate
increasing degrees of pathology.
Immunohistochemistry
Dewaxed sections were subjected to heat antigen retrie-
val in 10 mM Na-Citrate buffer (pH 6.0). After preincu-
bation in 30% donkey normal serum and 0.05% Triton-
X in PBS, sections were incubated overnight at 4°C with
primary antibody at optimized working dilution. Mouse
monoclonal antibody to plasma membrane calcium
ATPase 2 (PMCA2) (1:500, BD Biosciences, San Jose,
CA) used to visualize Purkinje neurons and their
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anti-mouse IgG (F(ab’)2 Ab, 1:200; Jackson ImmunoRe-
search) for 1 h, and a streptavidin-peroxidase complex
(Perkin-Elmer Life Sciences, Boston, MA) at 1:200 for 1
h plus tyramide-fluorescein (1:100 for 10 min; PerkinEl-
mer Life Sciences). Polyclonal rabbit antibody to glial
fibrillary acidic protein (GFAP) (DakoCytomation,
Glostrup, Denmark) was used at 1:5000 to detect astro-
cytes. Microglia/macrophages were visualized by ionized
calcium-binding adapter molecule-1 (Iba-1) rabbit anti-
body (1:500; Wako Chemicals, Richmond, VA, Wako,
Japan). The DyLight568-coupled F(ab’)2 secondary (anti-
rabbit IgG, 1:200; Jackson ImmunoResearch, Suffolk,
England) was used. Sections were coverslipped using
Vectashield mounting medium with DAPI (Vector
Laboratories, Burlingame, CA). The analysis of negative
controls (omission of primary antibody) was simulta-
neously performed in order to exclude the presence of
non-specific immunofluorescent staining, cross-immu-
nostaining, or fluorescence bleed-through. A Nikon
Eclipse E660 microscope with appropriate excitation and
emission filters for each fluorophore was used to acquire
representative images from the examined specimens.
Images were acquired with × 20 to × 40 objectives using
a digital camera (DMX1200, Nikon) driven by Niko-
nACT-1 software and were processed for printing using
Adobe Photoshop.
Statistical analysis
Comparisons between two groups were performed with
non-parametric Mann-Whitney test; comparisons
between 3 groups were submitted to non-parametric
Kruskal-Wallis variance analysis followed by two-by-two
Dunn’s comparison tests. Differences were considered
significant at p < 0.05. Analyses were performed with
GraphPad software (San Diego, CA, USA).
Results
PrPc ablation increases EAE clinical severity, duration and
associated neurohistopathological parameters
The increased severity of EAE clinical symptoms in mice
lacking PrPc was confirmed in 3 consecutive experi-
ments involving a total of 15 Prnp
-/- and 16 Prnp
+/+
mice. As shown in Figure 1 representative of one of
these experiments, after a similar initial phase extending
up to 15 dpi, clinical scores increased faster in the
Prnp
-/- group and remained higher. Differences reached
statistical significance at 24 dpi and remained significant
till 37 dpi (p < 0.05 by Mann-Whitney test). EAE was
not only more severe, but it resolved also more slowly
as reported in other studies. Histological analyses of
spinal cords were done in a subset of mice (n = 3/
group) sacrificed at 22 dpi, the earliest time point where
clinical scores started diverging significantly when
analyzing all mice. As shown in Figure 2, infiltration of
the spinal cord by immune cells was similar in Prnp
+/+
and Prnp
-/- mice in spite of the more severe neurologi-
cal symptoms in the latter group. Quantitative micro-
scopic examinations of hematoxylin stained sections
showed twice as many nuclei in the white matter of
spinal cord sections in MOG-challenged mice than in
PBS controls (p < 0.001 by variance analysis). But there
was no significant difference between MOG-challenged
Prnp
-/- and Prnp
+/+ mice (Figure 2F). In contrast,
Bielschowky’s staining revealed increased axonal damage
during EAE in Prnp
-/- mice compared to Prnp
+/+ mice
(Figure 3).
Most strikingly, examination at high magnification
showed the presence of enlarged axonal bulbs in Prnp
-/-
mice, a sign of severe damage (Figure 3F). Differences
between Prnp
-/- MOG-challenged mice and PBS con-
trols were significant by Dunn’s comparison test (p <
0.05), though differences between Prnp
-/- and Prnp
+/+
EAE mice did not reach p value < 0.05 (Figure 3G).
Increased EAE severity in PrPc-deprived mice is not
associated with abnormal anti-MOG immune responses
G i v e nt h ei m p l i c a t i o no fP r P ci ni m m u n er e s p o n s e s ,
notably through T-DC interactions [22], we tested the
possibility that the lack of PrPc on T cells may modify
their responses against myelin antigens, resulting in
more dramatic EAE manifestations as suggested in the
reported studies [30-32]. T cells from MOG-primed
Prnp
-/- and Prnp
+/+ mice were thus collected between
18 and 24 dpi, at the peak of EAE exacerbation, and
Figure 1 Exacerbated EAE in PrPc-ablated (Prnp
-/-) mice. Clinical
scores (mean ± SEM) in PrPc-deficient (black dots) versus PrP-
sufficient (black triangles) mice. Disease onset was identical in the
two groups (Prnp
-/-: 12.7 ± 0.3; Prnp
+/+: 12.4 ± 0.4). Clinical scores
began significantly diverging at 22 dpi after the initial peak of
disease. *: p < 0.05 by Mann-Whitney (n = 8-10/group).
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release. Serum samples collected at the same time were
used for antibody titration. As indicated in Figure 4A, T
cells proliferated to the same extent at all the concentra-
tions of MOG tested, irrespective of whether they were
PrPc-deficient or PrPc-sufficient, and despite marked
differences in clinical scores of those mice. In addition,
the frequencies of T cells secreting IFN-g and IL-17,
two cytokines of major importance in EAE pathogenesis,
were not significantly different (Figure 4B-C). Significant
amounts of circulating antibody against MOG were
detected at 1/50 serum diluti o ni nE A E - i n d u c e dm i c e ,
with no difference between wild type and PrPc-ablated
mice (Figure 4D). Sera of normal non-EAE-induced
mice were totally devoid of anti-MOG antibody (data
not shown). In addition, we verified that the number of
regulatory CD25+/FoxP3+ T cells which express high
levels of PrPc under normal conditions [39], was not
reduced in PrPc-deficient mice (data not shown). In
conclusion, we could not find any indication that
immune responses against the myelin-derived self
antigen were modified, 22 days after immunization, as a
consequence of PrPc ablation.
PrPc-deficient anti-MOG CD4+ T cells are not more
encephalitogenic than PrPc-sufficient controls
Although we did not find evidence to support the idea
that CD4+ T cells lacking PrPc adopted a stronger
inflammatory profile and were therefore more deleter-
ious than wild type T cells, we verified directly this
hypothesis by comparing disease development in
CD3ε
-/- mice adoptively transferred with anti-MOG T
cells expressing or not PrPc.
CD4+ T cells from the anti-MOG35-55 2D2 TCR
transgenic line [35] respectively backcrossed to Prnp
-/-
or to Prnp
+/+ B6 mice, were transferred into CD3ε
-/-
recipients challenged with MOG35-55 peptide plus per-
tussis toxin. As shown in Figure 5A-B and in Table 1,
2D2 T cells lacking PrPc far from being more encephali-
togenic caused a milder disease with a delayed onset and
lower clinical scores and with less weight loss and no
ataxia compared to the PrPc-sufficient counterparts.
Figure 2 No difference in mononucleated cell infiltration between EAE-induced Prnp
-/- and Prnp
+/+ mice. Hematoxylin stained sections of
ventral spinal cord at 22 dpi; (A) Prnp
+/+ EAE-induced mouse; (B) Prnp
-/- EAE-induced mouse and (C) non-EAE PBS/CFA control. (D) and (E) white
matter sections of a Prnp
-/- PBS control and a Prnp
-/- EAE mouse respectively. Scale bar: A-C, 200 μm; D-E, 56 μm. (F) average numbers of white
matter nuclei per spinal cord section of Prnp
+/+ and Prnp
-/- EAE mice and of PBS controls (n = 3/group). *: p < 0.001 versus controls (Dunn’s post
test analysis).
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neural cells rather than in immune cells
To determine the neural versus immune origin of EAE
exacerbation in mice lacking PrPc, we generated reci-
procal [Prnp
-/- >Prnp
+/+] and [Prnp
+/+ >Prnp
-/-] BM chi-
meras. This strategy has been widely used in EAE
studies to establish the tissue origin of effector mole-
cules that are ubiquitously expressed in the CNS and
the lymphoid system [40-42]. To control for an effect of
total body irradiation, a group of mice was lethally irra-
diated and restored with homologous Prnp
-/- or Prnp
+/+
BM. PBMC were phenotyped at 10 weeks post-transfer.
T and B cell subsets were normally reconstituted and
more than 90% of CD4+ T cells were of donor origin
(Table 2). Residual chimerism was the same irrespective
of donor/recipient combinations.
Total body irradiation exacerbated manifestation of
EAE in all the mice as a probable consequence of
increased blood brain barrier permeability and glial acti-
vation [43]. Neurological deficits started between 8 and
10 dpi in all the groups, but differences between chi-
meras were observed (Figure 6A). EAE was more severe
in [Prnp
+/+ >Prnp
-/-]t h a ni n[ Prnp
-/- >Prnp
+/+]m i c e( p
< 0.05 and 0.01 by Mann-Whitney test). Loss of body
weight (Figure 6B) and ataxia (Table 1), two parameters
of disease severity and of cerebellum dysfunction respec-
tively, were also more pronounced in [Prnp
+/+ >Prnp
-/-]
mice than in [Prnp
-/- >Prnp
+/+]m i c e( p <0 . 0 5a n d0 . 0 1
by Mann-Whitney test). Irradiation controls, reconsti-
tuted with homologous BM, reproduced the same pat-
tern of disease severity as heterologous chimeras (Figure
6A) confirming that differences between chimeras were
Figure 3 More severe axonal loss/damage in the white matter of Prnp
-/- mice. Sections of ventral spinal cord revealed by Bielschowsky’s
silver staining; (A) Prnp
+/+ EAE-induced mouse; (B) Prnp
-/- EAE-induced mouse and (C) non-EAE PBS/CFA control. (D) and (E) focus into the white
matter of ventral spinal cord from a Prnp
+/+ EAE mouse and a Prnp
-/- EAE mouse, respectively. (F) higher magnification in the damaged white
matter of a Prnp
-/- EAE mouse showing typical axonal bulb formation. Scale bars: A-C: 200 μm, D-E: 30 μm, F: 15 μm. (G) quantitative evaluation
of axonal damage in Prnp
+/+ versus Prnp
-/- EAE-induced mice, and wild type PBS controls (n = 3/group). *: p < 0.05 vs. PBS controls (Dunn’s post
test analysis).
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Interestingly, disease severity was comparable in [Prnp
-/-
>Prnp
-/-]a n di n[ Prnp
+/+ >Prnp
-/-] mice suggesting that
the absence of PrPc in the hematopoietic compartment
did not aggravate further the symptoms induced by the
absence of PrPc in the CNS.
Prnp-/-] chimeras",1,0,1,0,0pc,0pc,0pc,0pc>Cerebellar
alterations associated with EAE exacerbation in [Prnp
+/+
>Prnp
-/-] chimeras
The manifestation of severe ascending forms of EAE
leading in many cases to ataxia warranted histological
evaluation of the cerebellum. EAE predominantly targets
the spinal cord but can affect the cerebellar peduncles
[44]. Tissue samples from [Prnp
+/+ >Prnp
-/-]a n d
[Prnp
-/- >Prnp
+/+] mice were collected at the peak of the
active disease phase in order to assess immune cell infil-
tration, myelin degeneration, axonal damage and glial
activation. EAE exacerbation in [Prnp
+/+ >Prnp
-/-]w a s
not correlated with more massive infiltration of the
white matter by immune cells. Perivascular cellular infil-
trates were abundant in both combinations of chimeras.
However, foci appeared more extended in [Prnp
+/+
>Prnp
-/-] mice which developed an exacerbated disease
(Figure 7A-B). As anticipated, cerebella from [Prnp
+/+
>Prnp
-/-] chimeras displayed more severe axonal damage
revealed by Bielschowsky’s axonal staining of white mat-
ter tracts (Figure 7C-D). Areas of demyelination revealed
by Luxol fast blue staining were also more extended in
these mice (Figure 7E-F). As an additional parameter of
Figure 4 CD4+ T cells from Prnp
-/- and Prnp
+/+ EAE-induced mice respond similarly to MOG35-55.( A) In vitro proliferation of purified CD4+
T cells from 3 Prnp
-/- and 3 Prnp
+/+ primed mice tested individually. Thymidine incorporation was measured after 92 hours of culture. (B) and (C)
concentrations of IFN-g and IL-17 in supernatants collected at 48 hour of culture of MOG-primed CD4+ T cells in vitro reactivated with APC and
MOG peptide. (D) anti-PrP antibodies titrated by solid phase ELISA in individual sera of EAE-induced mice collected at 22 dpi.
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plasma membrane calcium ATPase 2 (PMCA2) whose
function is to extrude calcium from neurons and whose
expression is impaired in EAE and spinal cord trauma
[45,46]. In agreement with the above observations, loss
of PMCA2 immunoreactivity in Purkinje cell bodies and
their dendritic arborization in the molecular layer was
more pronounced in [Prnp
+/+ >Prnp
-/-]t h a ni n[ Prnp
-/-
>Prnp
+/+] mice indicating that Purkinje neuronal
damage correlates with disease severity in radiation chi-
meras (Figure 8A-B). Astrocytosis and microgliosis were
evaluated by GFAP and Iba-1 staining respectively.
Astrogliosis was observed in the cerebellar white matter
of all chimeras, and occurred especially around inflamed
vessels, where numerous hypertrophic GFAP positive
cells were present. Still, astrocytes in [Prnp
+/+ >Prnp
-/-]
chimeras presented more intense immunoreactivity and
thicker processes, both in the grey matter (Figure 8C-
D), and in the white matter (Figure 8E-F). Immunoreac-
tivity for Iba-1, a marker of blood-borne macrophages
and resident microglia, was also observed in the cerebel-
lar white and grey matter of both types of chimeras
(Figure 9). However, as for astrogliosis, Iba-1 immunor-
eactivity on macrophage-like cells was clearly much
higher in the white matter of [Prnp
+/+ >Prnp
-/-]e s p e -
cially around inflamed vessels (Figure 9B) indicating
increased neuroinflammation in cerebellar parenchyma.
In the grey matter, Iba-1 staining was restricted to rest-
ing and scattered activated microglial cells (with thick
processes), especially in the granule cell layer of both
types of chimeras (Figure 9C-D). In conclusion, clinical
exacerbation observed in chimeras in which the CNS
was PrPc-depleted correlated with more severe parench-
ymal damage and increased glial activation in
cerebellum.
Discussion
Lack of evidence supporting T cell implication in EAE
exacerbation
The common denominator to the multiple functions
attributed to PrPc is still elusive. In the immune system,
PrPc is viewed as a molecule of activation and
Table 1 Ataxia incidence during EAE in mice adoptively
transferred with encephalitogenic TCR-transgenic 2D2 T
cells and in BM chimeras
Mice Ataxia
[2D2 Prnp
+/+ > CD3ε
-/-] 2/5
[2D2 Prnp
-/- > CD3ε
-/-] 0/5
[Prnp
+/+ > Prnp
-/-] 5/7
[Prnp
-/- > Prnp
+/+] 0/7
Figure 5 Less severe EAE in CD3ε
-/- mice adoptively transferred with PrPc-deficient 2D2 T cells.( A) clinical scores (mean ± SEM). All the
mice transferred with PrPc-expressing effector T cells reached terminal stage disease (mean score 4.5) at 20 dpi whereas the average score in
the recipients of PrPc-deficient T cells was 1.7 at the same time point. (B) Corresponding weight loss in recipients of PrPc-expressing or deficient
2D2 T cells (mean ± SEM).
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Page 8 of 14regulation of adaptive immune responses, whereas in the
CNS, PrPc maintains the physiological integrity of the
system and protects neurons against various insults [7].
It is therefore crucial to dissect the specific contribution
of the prion protein in manifestations such as EAE
which involve the neural and immune systems. As pre-
viously reported [30-32], and as confirmed in the pre-
sent study, mice deprived of PrPc by genetic ablation or
by RNA interference develop worsened clinical and his-
topathological manifestations of EAE. At variance with
Tsutsui et al. and Hu et al., we did not observe an
acceleration of disease onset or increased leukocyte infil-
tration of the white matter. But in agreement with the
other studies [30-32], neurological scores were signifi-
cantly higher in PrPc-deprived mice and remissions
were clearly delayed. Accordingly, axonal damage,
revealed by Bielschowky’s staining was more pro-
nounced in the spinal cords of PrPc-deprived mice.
In view of our own results suggesting that PrPc
exerts a control on T cell responses [22], and of those
reported by Tsutsui et al. [31], Ingram et al. [30] and
Hu et al. [32], we anticipated to find differences in the
responses to MOG peptide of PrPc-deficient T cells
versus wild type T cells. Surprisingly, T cells derived
from Prnp
-/- mice and challenged with MOG35-55 pep-
tide proliferated to the same extent as controls, pro-
duced the same amounts of IFNg and IL-17 cytokines,
two major cytokines involved in EAE pathogenesis,
provided similar help to B cells for antibody produc-
tion, and contained identical proportions of regulatory
CD25+/FoxP3+ T lymphocytes which highly express
PrPc [39]. The present discrepancies may be the result
of the heterogeneity in mouse strains, of the variety of
encephalitogenic antigens, and of the protocols for T
cell assays. Even within the reported studies, observa-
tions diverged with respect to the robustness of cyto-
kine responses in Prnp
-/- mice and to the hierarchy
between Th1 and Th17 inflammatory T cells [30]. Our
results being based on a single PrP knock-out line
backcrossed on a B6 genetic background, we cannot
exclude the possibility that the discrepancies observed
with the above mentioned studies result from the use
of different PrPc-ablated strains on different genetic
backgrounds [30,31], or from differences in the metho-
dology of gene silencing [32]. An interesting possibility
of divergence with respect to the latter study could be
that at variance with pharmacological ablation by small
interfering ribonucleic acid (siRNA) which is limited in
time and in extension, genetic knockdown generates
long-term immunological compensatory mechanisms.
This eventuality cannot be formally excluded, even
though no such compensatory mechanisms have been
so far demonstrated either in the immune system, or in
the CNS [47]. It will be worth nevertheless verifying
that the present conclusions remain true irrespective of
the experimental conditions under which PrPc has
been ablated. Another probable source of discrepancy
is the heterogeneity of the T cell assay protocols. T
cells were either assayed in a naive state, by polyclonal
activation immediately after being collected ex vivo
[30] or were in vitro challenged with antigen present-
ing cells and peptides a few days only after in vivo
priming [31,32]. In contrast, T cells were presently
probed three weeks after in vivo challenge with
MOG35-55 peptide. At this time, a full-fledged response
Table 2 Hematopoietic reconstitution of irradiated
CD45.1
+ mice by CD45.2
+ BM
[Prnp
-/- > Prnp
+/+]
CD19+ CD4+ CD8+
CD45.1
+
CD45.2
+
CD45.1
+
CD45.2
+
CD45.1
+
CD45.2
+
#1 0.1 65.04 2.34 16.95 1.64 8.53
#2 0.14 57.56 2.86 18.34 2.28 11.45
#3 0.07 60.94 1.83 19.04 2.45 10.21
#4 0.04 64.02 2.31 17.24 1.79 8.86
#5 0.08 59.17 3.33 19.93 1.8 9.82
#6 0.03 65.27 2.86 17.31 1.57 8.41
#7 0.09 58.02 4.23 19.54 2.84 10.18
[Prnp
+/+ >
Prnp
-/-]
CD19+ CD4+ CD8+
CD45.1
+
CD45.2
+
CD45.1
+
CD45.2
+
CD45.1
+
CD45.2
+
#1 0.05 52.13 3.41 20.11 2.98 10.61
#2 0.09 56.37 3.59 21.66 3.1 10.46
#3 0.12 60.21 3.97 19.15 3.26 9.62
#4 0.15 59.91 3.89 18.88 3.28 9.83
#5 0.11 56.15 4.24 20.15 3.32 9.68
#6 0.2 60.52 3.27 17.23 2.59 8.88
#7 0.15 47.91 3.58 18.44 3.18 10.02
[Prnp
+/+ > Prnp
+/+]
CD19+ CD4+ CD8+
CD45.1
+
CD45.2
+
CD45.1
+
CD45.2
+
CD45.1
+
CD45.2
+
#1 0.08 65.16 2.24 18.17 1.5 9.07
#2 0.08 67.21 1.92 17.3 1.35 8.29
#3 0.04 63.49 1.3 16.96 0.7 8.88
#4 0.02 69.12 2.52 15.95 1.29 7.25
[Prnp
-/- > Prnp
-/-
]
CD19+ CD4+ CD8+
CD45.1
+
CD45.2
+
CD45.1
+
CD45.2
+
CD45.1
+
CD45.2
+
#1 0.12 52.03 5.18 22.91 3.46 11.66
#2 0.09 54.22 3.93 19,76 3.54 12.3
#3 0.12 57.48 4.3 20.02 2.82 11.06
PBMC samples were phenotyped 10 weeks post-transfer by cell-surface
staining. Lymphocyte percentages were assessed by flow cytometry
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Page 9 of 14to MOG had developed in vivo, and EAE exacerbation
in Prnp
-/- mice was clear-cut. If qualitative or quantita-
tive differences in T cell responses were at the origin
of disease worsening, they should have been evidenced
at this point. The fact that the responses of PrPc-defi-
cient T cells were modified at 7-10 dpi and appeared
normal at 22 dpi suggests that the alterations in
acquired immunity caused by PrPc-deficiency vanish
with time. Nevertheless, the absence of PrPc on T cells
may have a biological impact at the onset of some
immune reactions as illustrated by the reduced resis-
tance to sepsis of Prnp
-/- mice reported by Ingram and
colleagues [30], and by our own data measuring in vivo
T cell proliferation after only 6-day engraftment into
PrPc-ablated mice [22]. Still, whether an early altera-
tion of T-cell responsiveness may affect immune
responses that develop in the longer term such as EAE
requires further investigations. It should be emphasized
that Prnp
-/- mice have been frequently used for the
production of anti-scrapie hyperimmune sera and pro-
tective T cells [48], and that so far no obvious immu-
nological anomaly was reported. More direct evidence
for the implication of T cells in EAE exacerbation
could be obtained by showing that mice adoptively
transferred with encephalitogenic T cells that lack PrPc
develop a more aggressive disease than mice trans-
ferred with PrP-sufficient T cells. Such experiments
were not reported in any of the quoted studies. Our
own attempts at transferring TCR transgenic 2D2 T
cells generated in PrPc-positive and negative mice,
gave results opposite to what might have been
expected.
Experimental BM chimeras support the implication of the
CNS
The present data give support to a critical role of the
radio-resistant cells of the CNS in EAE exacerbation.
Chimeras with a PrPc-deficient immune system and a
PrPc-sufficient CNS are less affected than reciprocal chi-
meras with a PrPc-positive immune system and a PrPc-
deleted CNS. Disease begins earlier in the latter mice,
reaches significantly higher clinical scores and pro-
gresses in a majority of mice toward ataxia and terminal
stage sickness. Same differences were observed in irra-
diation controls restored with homologous BM. Disease
in [Prnp
-/- >Prnp
-/-] mice was definitively more aggres-
sive than in [Prnp
+/+ >Prnp
+/+] mice, but not more than
in [Prnp
+/+ >Prnp
-/-] chimeras, confirming that EAE
exacerbation resulted primarily from PrPc absence in
the CNS, and thus ruling out the possibility that the
lack of PrPc in the lymphoid system might be a less pre-
valent, but still effective contributor to disease
worsening.
The impact of PrPc absence on glial cells can be partly
dissociated from that on neurons
Currently, it is not possible to determine precisely
whether exacerbation of EAE in a PrP-deficient con-
text, originates from neuronal or glial dysfunction.
Morphological analyses of cerebella from chimeras dis-
play simultaneously increased Purkinje neuronal
degeneration visualized by a loss of PMCA2 staining
reflecting early neuronal damage [45] and stronger
glial activation assessed by GFAP and Iba-1 immuno-
labeling. The reduced resistance of PrPc-deprived
Figure 6 More severe EAE in chimeric mice with PrPc-depleted CNS cells.( A) clinical scores in reciprocal BM chimeras (continuous lines,
mean ± SEM) and irradiation controls restored with homologous BM (dashed lines, mean). Clinical scores begin diverging at 11 dpi. *: p < 0.05;
**: p < 0.01 by Mann-Whitney. (B) Corresponding weight loss (mean ± SEM) associated to EAE exacerbation in [Prnp
+/+ >Prnp
-/-] chimeras. Mann-
Whitney statistical difference between [Prnp
+/+ >Prnp
-/-] vs. [Prnp
-/- >Prnp
+/+] chimeras *: p < 0.05; **: p < 0.01.
Gourdain et al. Journal of Neuroinflammation 2012, 9:25
http://www.jneuroinflammation.com/content/9/1/25
Page 10 of 14neurons to autoimmune assaults might precipitate glio-
sis via the release of apoptotic bodies or cytokines.
Alternatively, the lack of PrPc in glial cells might
enhance their phagocytic activity, as demonstrated for
macrophages [28], or initiate an inflammatory cascade
resulting in increased neurodegeneration. The cellular
origin of PrPc deleterious effects being non-dissociable
in radiation chimeras, it is impossible to evaluate pre-
cisely the contribution of each cell subset (astrocytes
versus neurons). Studies that use transgenic mice with
PrPc expression targeted to the different cell popula-
tions could shed light into this issue. Contrary to
astrocytes, the impact of microglial PrPc can be distin-
g u i s h e df r o mt h a to fn e u r o n a lP r P c .M i c r o g l i ai s
composed of blood borne macrophages that differenti-
ate from BM progenitors and of resident microglial
cells which have a potential of self-renewal within the
brain [40,42,49]. Recent studies indicate that in chi-
meras conditioned by total body irradiation and
restored with mechanically dispersed BM suspensions,
as performed in this study, myeloid progenitors contri-
bute to the pool of blood borne macrophages that
replenish the resident microglia [50,51]. As microglia
in [Prnp
+/+ >Prnp
-/-] chimeras are mainly PrP-suffi-
cient, we conclude that neither blood borne macro-
phages nor resident cells contribute to disease
exacerbation. Thus, the hyperactived phenotype
reflected by large accumulations of Iba-1 positive cells
around inflamed vessels in [Prnp
+/+ >Prnp
-/-]c h i m e r a s
is probably secondary to neuronal damage.
PrPc protects neurons under autoimmune assault
Finally, the most likely interpretation of EAE worsen-
ing in PrPc-ablated mice and in [Prnp
+/+ >Prnp
-/-]
Figure 7 Representative histological stainings from cerebella of
chimeric mice with EAE. Left panels, [Prnp
-/- >Prnp
+/+] mouse.
Right panels, [Prnp
+/+ >Prnp
-/-]. (A-B) hematoxylin/eosin staining
showing white matter perivascular cellular infiltrates (black arrows)
that were more spread in [Prnp
+/+ >Prnp
-/-] than in [Prnp
-/- >Prnp
+/+]
mice. (C-D) Bielschowsky silver impregnation staining in the white
matter, showing reduced axonal staining in [Prnp
+/+ >Prnp
-/-] mouse
as compared to [Prnp
-/- >Prnp
+/+] mouse, despite the presence of
an inflammed vessel in the center in both examples. (E-F) Luxol
Fast blue staining showing a clear-cut demyelinating area (white
arrow) in [Prnp
+/+ >Prnp
-/-] mouse as compared to the normal
appearing white matter in [Prnp
-/- >Prnp
+/+] mouse. The dashed
lines point to the white matter/grey matter limit. wm, white matter.
Scale bars: 100 μm.
Figure 8 Representative immunostaininings for PMCA2 and
GFAP in the cerebellum of chimeric mice with EAE. Double
indirect immunofluorescence for PMCA2 and GFAP followed by
DAPI staining was performed on cerebellar sections from [Prnp
-/- >
Prnp
+/+] or [Prnp
+/+ > Prnp
-/-] mice with EAE. (A-B) PMCA2
immunofluorescence and (C-D) GFAP/DAPI stainings in
corresponding section of the grey matter. (E-F) GFAP/DAPI stainings
in the white matter (cerebellar peduncle). ml, molecular layer of the
grey matter; pl, Purkinje layer of the grey matter; gl, granular layer
of the grey matter; v, blood vessel; wm, white matter. Scale bar, 100
μm.
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sion not totally unexpected in view of the abundant lit-
erature ascribing neuroprotective and neurotrophic
functions to cellular prion protein [52,53]. Multiple
mechanisms leading to neurodegeneration, axonal
damage, demyelination, and oligodentrocyte death have
been identified in EAE [33]. They include calpain-
mediated caspase activation and apoptosis [54,55], oxi-
dative stress [56], glutamate mediated excitotoxicity
and calcium overload [57]. PrPc has the potential to
interfere with all these pathways. PrPc protects neu-
rons from Bax-mediated apoptosis [58], prevents cas-
pase-induced mitochondrial apoptosis [59] and favors
superoxide dismutase (SOD) activity [60,61], although
the latter point has been disputed [62]. PrPc also
down- regulates N-methyl-d-aspartate receptors on
neurons and exerts a protective effect against subse-
quent glutamate-mediated toxicity [63]. All these
actions of PrPc may protect against the damaging
effects of cellular oxidation, especially in vulnerable
neural cells such as neurons and oligodendrocytes. It is
interesting to note that Shadoo, another member of
the prion protein family [64], also expressed in the
CNS and exerting stress-protective activity [65] does
not compensate for the absence of PrPc in Prnp
-/-
mice. A major future objective will be to further
delineate the molecular pathways used by PrPc to pro-
tect the neurons from degeneration due to traumatic
insults, autoimmune reactions or neurotoxic amyloid
deposits.
Conclusion
The biological function of PrPc and the evolutionary
justification for its remarkable conservation in verte-
brates are still not resolved. A plethora of candidate
functions has been attributed to the prion protein,
mainly in the nervous and the immune systems. Here
we have examined the contribution of neural versus
lymphoid PrPc in the pathogenesis of EAE, a disease
model which develops at the confluence of the two sys-
tems. In contrast to previous reports inferring from T
cell responses in vitro that disease worsening in PrPc-
deficient mice had an immunological origin, we provide
evidence, based on reciprocal BM chimera experiments,
for the implication of CNS PrPc. These data highlight
once more the critical role of PrPc in protecting the
CNS from harming agents. They do not exclude the
importance of lymphoid PrPc in immune responses, par-
ticularly at their onset, but they underline the possibility
that evolution may have used the same gene for inde-
pendent and equally important functions as for CD3zeta
or semaphorins [66,67].
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